-
Je něco špatně v tomto záznamu ?
Adjuvant immunotherapy in patients with renal cell carcinoma and urothelial carcinoma: A systematic review and network meta-analysis
K. Mori, T. Yanagisawa, W. Fukuokaya, K. Iwatani, A. Matsukawa, S. Katayama, B. Pradere, E. Laukhtina, P. Rajwa, M. Moschini, S. Albisinni, W. Krajewski, A. Cimadamore, F. Del Giudice, J. Teoh, F. Urabe, S. Kimura, M. Murakami, S. Tsuzuki, J....
Jazyk angličtina Země Austrálie
Typ dokumentu metaanalýza, systematický přehled, časopisecké články, přehledy
PubMed
37840031
DOI
10.1111/iju.15319
Knihovny.cz E-zdroje
- MeSH
- adjuvancia imunologická terapeutické užití MeSH
- imunoterapie metody MeSH
- inhibitory kontrolních bodů terapeutické užití MeSH
- karcinom z přechodných buněk * farmakoterapie MeSH
- karcinom z renálních buněk * farmakoterapie MeSH
- lidé MeSH
- nádory ledvin * farmakoterapie MeSH
- nádory močového měchýře * MeSH
- nivolumab terapeutické užití MeSH
- randomizované kontrolované studie jako téma MeSH
- síťová metaanalýza MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- metaanalýza MeSH
- přehledy MeSH
- systematický přehled MeSH
Adjuvant immune checkpoint inhibitor therapies have radically altered the treatment landscape for renal cell carcinoma and urothelial carcinoma. However, studies have reported negative data regarding adjuvant immune checkpoint inhibitor therapies. Thus, this study aimed to assess the role of adjuvant immune checkpoint inhibitor therapy for both renal cell carcinoma and urothelial carcinoma. A systematic review and network meta-analysis were conducted in compliance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. Multiple databases were searched for articles published as of February 2023. Studies were deemed eligible if they evaluated disease-free survival in patients with renal cell carcinoma and urothelial carcinoma receiving adjuvant immune checkpoint inhibitor therapy. Five studies met the inclusion criteria. In a network meta-analysis, pembrolizumab was shown to be the most effective regimen for patients with renal cell carcinoma, whereas nivolumab was found to be the most effective regimen for patients with urothelial carcinoma. Additionally, these results were consistently observed in a sub-analysis of the T stage. The present analysis provides findings that support the usefulness of adjuvant nivolumab therapy in urothelial carcinoma and adjuvant pembrolizumab therapy in renal cell carcinoma, in agreement with the currently available guidelines. However, the caveat is that the randomized controlled trials included in this analysis differed in important respects despite being similar in study design. Therefore, with these differences in mind, care needs to be taken when selecting patients for these immune checkpoint inhibitor therapies to maximize their benefits.
Department of Medical Area Institute of Pathological Anatomy University of Udine Udine Italy
Department of Minimally Invasive and Robotic Urology Wrocław Medical University Wrocław Poland
Department of Urology 2nd Faculty of Medicine Charles University Prague Czech Republic
Department of Urology La Croix du Sud Hospital Quint Fonsegrives France
Department of Urology Medical University of Silesia Zabrze Poland
Department of Urology Medical University of Vienna Vienna Austria
Department of Urology San Raffaele Hospital and Scientific Institute Milan Italy
Department of Urology Stanford University School of Medicine Stanford California USA
Department of Urology The Jikei University School of Medicine Tokyo Japan
Department of Urology University of Texas Southwestern Medical Center Dallas Texas USA
Department of Urology Weill Cornell Medical College New York New York USA
Institute for Urology and Reproductive Health Sechenov University Moscow Russia
Karl Landsteiner Institute of Urology and Andrology Vienna Austria
Research Division of Urology Department of Special Surgery The University of Jordan Amman Jordan
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24007820
- 003
- CZ-PrNML
- 005
- 20240423160309.0
- 007
- ta
- 008
- 240412s2024 at f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/iju.15319 $2 doi
- 035 __
- $a (PubMed)37840031
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a at
- 100 1_
- $a Mori, Keiichiro $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan $u Department of Urology, Medical University of Vienna, Vienna, Austria $1 https://orcid.org/0000000261476569
- 245 10
- $a Adjuvant immunotherapy in patients with renal cell carcinoma and urothelial carcinoma: A systematic review and network meta-analysis / $c K. Mori, T. Yanagisawa, W. Fukuokaya, K. Iwatani, A. Matsukawa, S. Katayama, B. Pradere, E. Laukhtina, P. Rajwa, M. Moschini, S. Albisinni, W. Krajewski, A. Cimadamore, F. Del Giudice, J. Teoh, F. Urabe, S. Kimura, M. Murakami, S. Tsuzuki, J. Miki, K. Miki, SF. Shariat, T. Kimura, European Association of Urology-Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU)
- 520 9_
- $a Adjuvant immune checkpoint inhibitor therapies have radically altered the treatment landscape for renal cell carcinoma and urothelial carcinoma. However, studies have reported negative data regarding adjuvant immune checkpoint inhibitor therapies. Thus, this study aimed to assess the role of adjuvant immune checkpoint inhibitor therapy for both renal cell carcinoma and urothelial carcinoma. A systematic review and network meta-analysis were conducted in compliance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. Multiple databases were searched for articles published as of February 2023. Studies were deemed eligible if they evaluated disease-free survival in patients with renal cell carcinoma and urothelial carcinoma receiving adjuvant immune checkpoint inhibitor therapy. Five studies met the inclusion criteria. In a network meta-analysis, pembrolizumab was shown to be the most effective regimen for patients with renal cell carcinoma, whereas nivolumab was found to be the most effective regimen for patients with urothelial carcinoma. Additionally, these results were consistently observed in a sub-analysis of the T stage. The present analysis provides findings that support the usefulness of adjuvant nivolumab therapy in urothelial carcinoma and adjuvant pembrolizumab therapy in renal cell carcinoma, in agreement with the currently available guidelines. However, the caveat is that the randomized controlled trials included in this analysis differed in important respects despite being similar in study design. Therefore, with these differences in mind, care needs to be taken when selecting patients for these immune checkpoint inhibitor therapies to maximize their benefits.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a karcinom z renálních buněk $x farmakoterapie $7 D002292
- 650 12
- $a karcinom z přechodných buněk $x farmakoterapie $7 D002295
- 650 _2
- $a nivolumab $x terapeutické užití $7 D000077594
- 650 _2
- $a síťová metaanalýza $7 D000071076
- 650 _2
- $a inhibitory kontrolních bodů $x terapeutické užití $7 D000082082
- 650 12
- $a nádory močového měchýře $7 D001749
- 650 _2
- $a imunoterapie $x metody $7 D007167
- 650 _2
- $a adjuvancia imunologická $x terapeutické užití $7 D000276
- 650 12
- $a nádory ledvin $x farmakoterapie $7 D007680
- 650 _2
- $a randomizované kontrolované studie jako téma $7 D016032
- 655 _2
- $a metaanalýza $7 D017418
- 655 _2
- $a systematický přehled $7 D000078182
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Yanagisawa, Takafumi $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan $u Department of Urology, Medical University of Vienna, Vienna, Austria $1 https://orcid.org/0000000274100712
- 700 1_
- $a Fukuokaya, Wataru $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan $1 https://orcid.org/000000031044912X
- 700 1_
- $a Iwatani, Kosuke $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
- 700 1_
- $a Matsukawa, Akihiro $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan $1 https://orcid.org/000000023324762X
- 700 1_
- $a Katayama, Satoshi $u Department of Urology, Medical University of Vienna, Vienna, Austria $u Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan $1 https://orcid.org/0000000283772457
- 700 1_
- $a Pradere, Benjamin $u Department of Urology, La Croix du Sud Hospital, Quint Fonsegrives, France
- 700 1_
- $a Laukhtina, Ekaterina $u Department of Urology, Medical University of Vienna, Vienna, Austria $u Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia $1 https://orcid.org/0000000289530272
- 700 1_
- $a Rajwa, Pawel $u Department of Urology, Medical University of Vienna, Vienna, Austria $u Department of Urology, Medical University of Silesia, Zabrze, Poland
- 700 1_
- $a Moschini, Marco $u Department of Urology, San Raffaele Hospital and Scientific Institute, Milan, Italy $1 https://orcid.org/0000000230842458
- 700 1_
- $a Albisinni, Simone $u Urology Unit, Department of Surgical Sciences, Tor Vergata University Hospital, University of Rome Tor Vergata, Rome, Italy $1 https://orcid.org/0000000155293064
- 700 1_
- $a Krajewski, Wojciech $u Department of Minimally Invasive and Robotic Urology, Wrocław Medical University, Wrocław, Poland
- 700 1_
- $a Cimadamore, Alessia $u Department of Medical Area (DAME), Institute of Pathological Anatomy, University of Udine, Udine, Italy
- 700 1_
- $a Del Giudice, Francesco $u Department of Maternal-Infant and Urological Sciences, "Sapienza" University of Rome, Policlinico Umberto I Hospital, Rome, Italy $u Department of Urology, Stanford University School of Medicine, Stanford, California, USA $1 https://orcid.org/0000000338655988
- 700 1_
- $a Teoh, Jeremy $u Department of Surgery, Faculty of Medicine, S.H. Ho Urology Centre, The Chinese University of Hong Kong, Hong Kong, China $1 https://orcid.org/0000000293612342
- 700 1_
- $a Urabe, Fumihiko $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan $1 https://orcid.org/0000000225998183
- 700 1_
- $a Kimura, Shoji $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
- 700 1_
- $a Murakami, Masaya $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
- 700 1_
- $a Tsuzuki, Shunsuke $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan $1 https://orcid.org/0000000161644684
- 700 1_
- $a Miki, Jun $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan $1 https://orcid.org/0000000246388640
- 700 1_
- $a Miki, Kenta $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
- 700 1_
- $a Shariat, Shahrokh F $u Department of Urology, Medical University of Vienna, Vienna, Austria $u Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia $u Research Division of Urology, Department of Special Surgery, The University of Jordan, Amman, Jordan $u Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas, USA $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic $u Department of Urology, Weill Cornell Medical College, New York, New York, USA $u Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria
- 700 1_
- $a Kimura, Takahiro $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan $1 https://orcid.org/0000000256731553
- 710 2_
- $a European Association of Urology-Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU)
- 773 0_
- $w MED00007209 $t International journal of urology $x 1442-2042 $g Roč. 31, č. 1 (2024), s. 25-31
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37840031 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240412 $b ABA008
- 991 __
- $a 20240423160306 $b ABA008
- 999 __
- $a ok $b bmc $g 2081675 $s 1217587
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 31 $c 1 $d 25-31 $e 20231015 $i 1442-2042 $m International journal of urology $n Int J Urol $x MED00007209
- LZP __
- $a Pubmed-20240412
